

Terence H Rabbitts

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4780779/publications.pdf>

Version: 2024-02-01

74
papers

4,302
citations

109137

35
h-index

110170

64
g-index

79
all docs

79
docs citations

79
times ranked

4908
citing authors

#	ARTICLE	IF	CITATIONS
1	The Oncogenic Cysteine-rich LIM domain protein Rbtn2 is essential for erythroid development. <i>Cell</i> , 1994, 78, 45-57.	13.5	582
2	Translocations, master genes, and differences between the origins of acute and chronic leukemias. <i>Cell</i> , 1991, 67, 641-644.	13.5	281
3	Activation of the T-Cell Oncogene LMO2 after Gene Therapy for X-Linked Severe Combined Immunodeficiency. <i>New England Journal of Medicine</i> , 2004, 350, 913-922.	13.9	257
4	A map of the human immunoglobulin VH locus completed by analysis of the telomeric region of chromosome 14q. <i>Nature Genetics</i> , 1994, 7, 162-168.	9.4	247
5	Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study. <i>Science</i> , 2021, 374, 472-478.	6.0	228
6	The <i>Lmo2</i> Oncogene Initiates Leukemia in Mice by Inducing Thymocyte Self-Renewal. <i>Science</i> , 2010, 327, 879-883.	6.0	201
7	ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2014, 124, 3738-3747.	0.6	198
8	Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS. <i>EMBO Journal</i> , 2007, 26, 3250-3259.	3.5	141
9	The LMO2 T-Cell Oncogene Is Activated via Chromosomal Translocations or Retroviral Insertion during Gene Therapy but Has No Mandatory Role in Normal T-Cell Development. <i>Molecular and Cellular Biology</i> , 2003, 23, 9003-9013.	1.1	123
10	Intrabodies based on intracellular capture frameworks that bind the RAS protein with high affinity and impair oncogenic transformation. <i>EMBO Journal</i> , 2003, 22, 1025-1035.	3.5	120
11	Single Domain Intracellular Antibodies: A Minimal Fragment For Direct In Vivo Selection of Antigen-specific Intrabodies. <i>Journal of Molecular Biology</i> , 2003, 331, 1109-1120.	2.0	107
12	Chromosome translocation can occur on either side of the c-myc oncogene in Burkitt lymphoma cells. <i>Nature</i> , 1984, 308, 286-288.	13.7	102
13	Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment. <i>Nature Communications</i> , 2018, 9, 3169.	5.8	100
14	Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 2545-2550.	3.3	96
15	Intracellular antibody capture technology: application to selection of intracellular antibodies recognising the BCR-ABL oncogenic protein. <i>Journal of Molecular Biology</i> , 2002, 317, 85-94.	2.0	87
16	Intracellular antibodies and challenges facing their use as therapeutic agents. <i>Trends in Molecular Medicine</i> , 2003, 9, 390-396.	3.5	87
17	Structural and functional characterization of a DARPin which inhibits Ras nucleotide exchange. <i>Nature Communications</i> , 2017, 8, 16111.	5.8	77
18	PCRPI: Presaging Critical Residues in Protein interfaces, a new computational tool to chart hot spots in protein interfaces. <i>Nucleic Acids Research</i> , 2010, 38, e86-e86.	6.5	70

#	ARTICLE	IF	CITATIONS
19	A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS. <i>Nature Communications</i> , 2020, 11, 3233.	5.8	68
20	KRAS-specific inhibition using a DARPIn binding to a site in the allosteric lobe. <i>Nature Communications</i> , 2019, 10, 2607.	5.8	66
21	Requirement for Lyl1 in a model of Lmo2-driven early T-cell precursor ALL. <i>Blood</i> , 2013, 122, 2093-2103.	0.6	62
22	Commonality but Diversity in Cancer Gene Fusions. <i>Cell</i> , 2009, 137, 391-395.	13.5	61
23	LMO2 at 25 years: a paradigm of chromosomal translocation proteins. <i>Open Biology</i> , 2015, 5, 150062.	1.5	58
24	The LIM-domain protein Lmo2 is a key regulator of tumour angiogenesis: a new anti-angiogenesis drug target. <i>Oncogene</i> , 2002, 21, 1309-1315.	2.6	45
25	Exploring the surfaceome of Ewing sarcoma identifies a new and unique therapeutic target. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 3603-3608.	3.3	42
26	Chromosomal translocation products engender new intracellular therapeutic technologies. <i>Nature Medicine</i> , 2003, 9, 383-386.	15.2	41
27	Blocking oncogenic RAS enhances tumour cell surface MHC class I expression but does not alter susceptibility to cytotoxic lymphocytes. <i>Molecular Immunology</i> , 2014, 58, 160-168.	1.0	41
28	BRET-based RAS biosensors that show a novel small molecule is an inhibitor of RAS-effector protein-protein interactions. <i>ELife</i> , 2018, 7, .	2.8	41
29	Unusual forms of T cell \hat{I}^3 mRNA in a human T cell leukemia cell line: Implications for \hat{I}^3 gene expression. <i>European Journal of Immunology</i> , 1987, 17, 1729-1736.	1.6	39
30	Chromosomal translocation master genes, mouse models and experimental therapeutics. <i>Oncogene</i> , 2001, 20, 5763-5777.	2.6	38
31	Interrogation of genomes by molecular copy-number counting (MCC). <i>Nature Methods</i> , 2006, 3, 447-453.	9.0	38
32	Intracellular antibodies and cancer: New technologies offer therapeutic opportunities. <i>BioEssays</i> , 2010, 32, 589-598.	1.2	38
33	Protocol for the selection of single-domain antibody fragments by third generation intracellular antibody capture. <i>Nature Protocols</i> , 2010, 5, 67-92.	5.5	38
34	De novo production of diverse intracellular antibody libraries. <i>Nucleic Acids Research</i> , 2003, 31, 23e-23.	6.5	36
35	Targeting LMO2 with a Peptide Aptamer Establishes a Necessary Function in Overt T-Cell Neoplasia. <i>Cancer Research</i> , 2009, 69, 4784-4790.	0.4	36
36	Single Domain Intracellular Antibodies from Diverse Libraries. <i>Journal of Biological Chemistry</i> , 2011, 286, 3707-3716.	1.6	35

#	ARTICLE	IF	CITATIONS
37	Functional Intracellular Antibody Fragments Do Not Require Invariant Intra-domain Disulfide Bonds. <i>Journal of Molecular Biology</i> , 2008, 376, 749-757.	2.0	34
38	Lipid-mRNA Nanoparticle Designed to Enhance Intracellular Delivery Mediated by Shock Waves. <i>ACS Applied Materials & Interfaces</i> , 2019, 11, 10481-10491.	4.0	32
39	Interfering with protein-protein interactions: Potential for cancer therapy. <i>Cell Cycle</i> , 2008, 7, 1569-1574.	1.3	28
40	A super-potent tetramerized ACE2 protein displays enhanced neutralization of SARS-CoV-2 virus infection. <i>Scientific Reports</i> , 2021, 11, 10617.	1.6	28
41	Selection and Characterization of a Nanobody Biosensor of GTP-Bound RHO Activities. <i>Antibodies</i> , 2019, 8, 8.	1.2	26
42	A Complete Map of the Human Immunoglobulin V _H Locus. <i>Annals of the New York Academy of Sciences</i> , 1995, 764, 43-46.	1.8	25
43	Multimeric antibodies with increased valency surpassing functional affinity and potency thresholds using novel formats. <i>MAbs</i> , 2020, 12, 1752529.	2.6	19
44	Salmonella-based platform for efficient delivery of functional binding proteins to the cytosol. <i>Communications Biology</i> , 2020, 3, 342.	2.0	14
45	Characterization of the Lmo4 gene encoding a LIM-only protein: genomic organization and comparative chromosomal mapping. <i>Mammalian Genome</i> , 1999, 10, 1089-1094.	1.0	13
46	A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency. <i>Antiviral Research</i> , 2021, 194, 105147.	1.9	11
47	T cell tumorigenesis in Lmo2 transgenic mice is independent of V-D-J recombinase activity. <i>Oncogene</i> , 2001, 20, 4412-4415.	2.6	10
48	Nonreciprocal chromosomal translocations in renal cancer involve multiple DSBs and NHEJ associated with breakpoint inversion but not necessarily with transcription. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 402-409.	1.5	10
49	Intracellular antibody capture: A molecular biology approach to inhibitors of protein-protein interactions. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2014, 1844, 1970-1976.	1.1	10
50	Selection of complementary single-variable domains for building monoclonal antibodies to native proteins. <i>Nucleic Acids Research</i> , 2009, 37, e41-e41.	6.5	8
51	Intracellular immunization against HIV infection with an intracellular antibody that mimics HIV integrase binding to the cellular LEDGF protein. <i>Scientific Reports</i> , 2017, 7, 16869.	1.6	8
52	Surfaceome interrogation using an RNA-seq approach highlights leukemia initiating cell biomarkers in an LMO2 T cell transgenic model. <i>Scientific Reports</i> , 2019, 9, 5760.	1.6	8
53	Bioluminescence Resonance Energy Transfer 2 (BRET2)-Based RAS Biosensors to Characterize RAS Inhibitors. <i>Current Protocols in Cell Biology</i> , 2019, 83, e83.	2.3	8
54	A cell-based screening method using an intracellular antibody for discovering small molecules targeting the translocation protein LMO2. <i>Science Advances</i> , 2021, 7, .	4.7	8

#	ARTICLE	IF	CITATIONS
55	Intracellular Antibody Capture (IAC) Methods for Single Domain Antibodies. <i>Methods in Molecular Biology</i> , 2012, 911, 151-173.	0.4	7
56	Masked antisense: a molecular configuration for discriminating similar RNA targets. <i>EMBO Reports</i> , 2000, 1, 59-64.	2.0	6
57	Single Domain Antibody Fragments as Drug Surrogates Targeting Protein-Protein Interactions inside Cells. <i>Antibodies</i> , 2013, 2, 306-320.	1.2	6
58	Cancer cell killing by target antigen engagement with engineered complementary intracellular antibody single domains fused to pro-caspase3. <i>Scientific Reports</i> , 2019, 9, 8553.	1.6	6
59	Pan RAS-binding compounds selected from a chemical library by inhibiting interaction between RAS and a reduced affinity intracellular antibody. <i>Scientific Reports</i> , 2021, 11, 1712.	1.6	6
60	Implementing a method for engineering multivalency to substantially enhance binding of clinical trial anti-SARS-CoV-2 antibodies to wildtype spike and variants of concern proteins. <i>Scientific Reports</i> , 2021, 11, 10475.	1.6	6
61	An antibody-drug conjugate with intracellular drug release properties showing specific cytotoxicity against CD7-positive cells. <i>Leukemia Research</i> , 2021, 108, 106626.	0.4	6
62	Chromosomal breakpoints hit the spot. <i>Nature Medicine</i> , 1997, 3, 496-497.	15.2	4
63	A non-cell autonomous mouse model of CNS haemangioblastoma mediated by mutant KRAS. <i>Scientific Reports</i> , 2017, 7, 44899.	1.6	4
64	Immunopolymer Lipid Nanoparticles for Delivery of Macromolecules to Antigen-Expressing Cells. <i>ACS Applied Bio Materials</i> , 2020, 3, 8481-8495.	2.3	4
65	Cloning, purification and structure determination of the HIV integrase-binding domain of lens epithelium-derived growth factor. <i>Acta Crystallographica Section F, Structural Biology Communications</i> , 2018, 74, 143-149.	0.4	3
66	Competitive SPR using an intracellular anti-LMO2 antibody identifies novel LMO2-interacting compounds. <i>Journal of Immunological Methods</i> , 2021, 494, 113051.	0.6	2
67	Immunoglobulin VH-T cell receptor C δ fusion mRNA resulting from chromosome inversion include the T cell-associated 5 α exon ET. <i>European Journal of Immunology</i> , 1992, 22, 2745-2748.	1.6	1
68	Of methods and mapping. <i>Nature Medicine</i> , 1999, 5, 24-25.	15.2	1
69	ETV6: Its Role in Mouse Development and Leukaemogenesis Using Knock-Out and Knock-In Models.. <i>Blood</i> , 2007, 110, 461-461.	0.6	1
70	A Cell-based Screening Method Using an Intracellular Antibody for Discovering Small Molecules Targeting Hard-to-drug Proteins. <i>Bio-protocol</i> , 2022, 12, e4324.	0.2	1
71	Potential Z-DNA between exons of human secreted and membrane immunoglobulin heavy-chain μ -gene. <i>Biochemical Society Transactions</i> , 1984, 12, 863-863.	1.6	0
72	The LMO2 Master Gene; Its Role as a Transcription Regulator Determining Cell Fate in Leukemogenesis and in Hematopoiesis. , 0, , 483-495.		0

#	ARTICLE	IF	CITATIONS
73	Abstract LB-068: From intracellular antibody fragments to small molecule inhibitors of mutant KRAS. , 2017, , .		0
74	LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma. Clinics in Oncology, 2017, 2, 1183.	0.0	0